Image Credit: Canva
The main cause of death globally is still heart disease. Heart attacks may occur suddenly without any warning signs. However, in the film industry, intense chest pain would be portrayed for a heart attack. In actuality, many patients have slight symptoms that go unnoticed until the time of their heart attack days or even weeks prior to that.
Heart attacks do not always announce themselves with dramatic chest pain. Often, they manifest in subtle, easy-to-dismiss ways. Recognizing these overlooked warning signs and taking proactive steps toward cardiovascular health can save lives. If you or someone you know experiences any of these symptoms, seeking immediate medical care is crucial. Prioritizing heart health today can help prevent life-threatening complications in the future.
1. Discomfort Pressure in the Chest
One of the earliest and most common warning signs of an impending heart attack is pressure, tightness, or fullness in the chest. This pain is not typically sharp and sudden, like most people associate with a heart attack, but it can be intermittent, coming in waves, and lasting for several minutes before fading away. According to the American Heart Association, this is one of the red flags when accompanied by exertion. If you have persistent chest pressure, you should call emergency services immediately.
2. Pain Radiating to Other Parts of the Body
The well-known symptom of chest pain can also manifest discomfort related to a heart attack as pain radiating to other parts of the body. It is not unusual for people experiencing this kind of heart attack to report feeling pain in the shoulders, arms, back, neck, and even jaw. The vagus nerve is one that connects the heart to the brain, abdomen, and neck. The pain may be referred to these regions. In case you experience a sudden, unexplained pain in these regions, especially when exercising, seek a doctor's opinion.
3. Dizziness and Lightheadedness
Feeling dizziness upon standing up quickly or missing a meal is common, but unexplained dizziness often with chest pain or shortness of breath is the first sign of heart attack. Sudden hypotension can seriously decrease the blood supply to the brain and cause dizziness. Dizziness that does not go away on its own should not be ignored.
4. Unexplained Fatigue
It often happens that excessive tiredness, particularly in a busy lifestyle, is considered trivial, but ongoing fatigue, mostly in women, is a predictor of heart failure. According to some studies, extreme fatigue often starts a month before a heart attack, primarily in women. This is simply because the heart cannot pump well enough, leaving insufficient oxygen available to muscles and organs. Consult a healthcare professional if you become increasingly tired over time, yet are getting all the rest in the world.
5. Nausea, Indigestion, or Stomach Pain
Digestive problems like nausea, vomiting, or indigestion are often mistaken for acid reflux or food poisoning. However, these symptoms can also indicate reduced blood flow to the digestive tract, a common precursor to heart attacks. If you experience gastrointestinal distress alongside other symptoms like dizziness or chest discomfort, it's important to seek medical advice immediately.
6. Cold Sweats and Excessive Perspiration
Without apparent reason, a heart attack might be signaled by sudden sweating without any exercise or hot weather conditions. The heart's inability to function properly creates the body's "fight or flight" reaction, which means excessive sweating will occur. Be aware of your body and never ignore a cold sweat, particularly if it coincides with other symptoms.
7. Heart palpitations or irregular heartbeat
A racing or irregular heartbeat can be a normal reaction to stress or caffeine consumption. However, regular or unprovoked heart palpitations may indicate that the heart is under duress. If the heart is not getting enough oxygen-rich blood, it can start to beat irregularly. If you experience palpitations along with dizziness, chest pain, or shortness of breath, you should see a doctor right away.
8. Shortness of Breath
If suddenly climbing stairs or performing other everyday activities becomes a problem, then there may be a heart issue. Shortness of breath usually occurs with heart conditions because the circulation is not adequate and less oxygen is provided to the lungs. This symptom can occur either with or without chest pain and is an important indicator of the presence of underlying heart disease. If you find yourself experiencing sudden unexplained breathlessness, then seek a healthcare provider as soon as possible.
Early detection of these symptoms and early intervention can help avoid a life-threatening heart attack. You should visit a doctor if you feel the following symptoms:
Although heart attacks may come out of nowhere, lifestyle plays an important role in reducing a patient's risk; here are some heart-healthy habits to consider:
Take on a Heart-Healthy Diet: Focus on consuming whole foods, lean proteins, healthy fats, and fiber-rich fruits and vegetables. Try to limit processed foods, saturated fats, and added sugars.
Stay Active: Engage in at least 30 minutes of moderate physical activity most days of the week to strengthen your heart and improve blood circulation.
Smoking. Smoking is probably the single largest risk factor for heart disease. If you are a smoker, quitting can easily be the single best thing you can do to improve your heart health.
Deal with Stress: Chronic stress leads to heart disease. Relaxed people through various relaxation techniques including yoga, meditation, and even deep breathing, have lesser stresses.
Regular health checks Monitor blood pressure, cholesterol levels, and blood sugar on a regular basis. The risk factors' early detection can help avoid serious complications.
Credit: iStock
Beyond weight loss and diabetes control, GLP-1 drugs may offer mental health benefits by reducing the need for psychiatric hospital care among people with schizophrenia and type 2 diabetes (T2D), according to a new study published in The Lancet Psychiatry.
The findings showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and emergency department visits among people with both conditions.
Also read: Exclusive: GLP-1 Drugs Are The ‘New Statins’, Says University Hospital Birmingham Professor
Researchers from Deakin University and the University of Queensland in Australia analyzed US health records of more than 70,000 adults with schizophrenia and T2D who received treatment between January 2018 and October 2026.
The researchers found that people taking GLP-1 drugs were:
GLP-1 use was also associated with fewer psychiatric emergency department visits. Compared with the same groups, users were:
Further, when the researchers analyzed individual drugs, the association was observed with semaglutide, liraglutide, and tirzepatide, but not dulaglutide.
Read More: Ozempic Baby: Can GLP-1 Drugs Help Women With PMOS Conceive?
The researchers cautioned that the observational study cannot establish that GLP-1 drugs directly reduce the need for acute psychiatric care.
They said the medications should not be considered primary psychiatric treatments or prescribed solely to reduce psychiatric hospitalizations and emergency visits.
Instead, the findings point to a potential additional benefit when GLP-1 drugs are prescribed for appropriate metabolic indications as part of integrated cardiometabolic and mental health care.
“The findings suggest that lower psychiatric acute-care use could be a favourable secondary benefit when GLP-1-based therapies are clinically indicated for metabolic management,” the researchers said.
They added that randomized clinical trials and mechanistic studies are needed to determine whether the drugs have a direct effect on psychiatric outcomes. Further research should also investigate their potential benefits in people with schizophrenia who do not have T2D.
Schizophrenia is a serious psychiatric disorder associated with disability, other health conditions, and premature mortality. Cardiometabolic diseases, including T2D, contribute substantially to this burden.
Studies suggest that diabetes may be up to five times more common among people with schizophrenia than among those without the condition. Approximately one in five people with schizophrenia may also have diabetes.
Several factors may contribute to this increased risk, including:
GLP-1 receptor agonists are an established class of medications used to manage T2D and, in some cases, obesity. Their potential role in people with schizophrenia is of growing interest because of the high burden of metabolic disease in this population.
However, whether these medications directly improve psychiatric outcomes remains uncertain.
The latest findings suggest that GLP-1 treatment may be associated with reduced use of acute psychiatric care among people with schizophrenia and T2D. Further clinical trials are needed before any direct mental health benefit can be established.
Credit: iStock
Originally developed to treat type 2 diabetes and obesity, GLP-1 receptor agonists have shown benefits beyond blood sugar control and weight loss, including for cardiovascular and kidney health.
Some women, particularly those with polyendocrine metabolic ovarian syndrome (PMOS), formerly known
as PCOS, have reported conceiving after taking these medications.
Although GLP-1 drugs can support weight loss and improve metabolic health, evidence that they directly improve fertility remains limited.
For 30-year-old Ashlee Amborn, pregnancy was challenging. According to ABC News, she had PMOS, one functioning fallopian tube and half a uterus, which complicated her chances of conceiving naturally.
After years of fertility treatments, she conceived her first two children. Four months after her second child's birth, she became pregnant again.
Amborn said a GLP-1 drug prescribed to manage her PMOS symptoms, including inflammation and hormonal imbalances, helped her conceive. She became pregnant after taking the medication for a month.
"It was kind of these mixed emotions of, 'Holy cow, I'm pregnant,'" Amborn said. "I did this on my own without fertility treatment. All it took was a GLP-1."
Also read: Sorority Rush Sees Ozempic Trend: What Young Women Should Know Before Using GLP-1 Drugs
A recent review published in the Journal of the Brazilian Reproduction Association (JBRA) Assisted Reproduction suggests a possible association between GLP-1 use and improved fertility outcomes in women with obesity and PMOS, particularly those also taking metformin, a medication used to manage blood sugar.
Weight loss and improved insulin sensitivity may support ovulation and reduce ovarian dysfunction. However, more research is needed to establish whether these medications improve pregnancy or live-birth rates.
Dr. Jacinta Anyaoku, a physician at Maven Clinic specializing in obesity and women's health in midlife, told ABC News that research has not established a direct link between GLP-1 use and ovulation rates, although she has observed potential benefits among her patients.
"When you lose weight, your inflammation goes down," Anyaoku said. "It actually can help with improving your rate of ovulation. Your egg quality could potentially improve if you have reduced inflammation, and so these are all potential effects that come with GLP-1 use."
Sharrón L. Manuel, a board-certified OB/GYN and reproductive endocrinology specialist at HRC Fertility, attributes the reported "Ozempic Baby Boom" largely to weight loss and improved metabolic health, which may help restore ovulation.
Excess body weight can disrupt the hypothalamic-pituitary-ovarian (HPO) axis, contribute to insulin resistance and affect egg and uterine lining quality.
Manuel also points to preliminary research suggesting GLP-1 drugs may influence reproductive function through hormonal regulation, reduced inflammation and improved insulin sensitivity. However, preclinical findings involving ovarian function and endometrial receptivity require further investigation in humans.
Read More: GLP-1 Drugs Ozempic, Zepbound Use Rises 24-Fold Among American Women After Childbirth
GLP-1 drugs should not be used during pregnancy. Women planning to conceive should consult their healthcare professional about stopping treatment. For semaglutide, prescribing guidance recommends discontinuation at least two months before a planned pregnancy.
Women should also seek medical advice about using these medications while breastfeeding.
The American College of Obstetricians and Gynecologists advises against weight-loss medications during pregnancy. Women considering GLP-1 treatment should discuss the risks, benefits and timing with their healthcare professional, particularly if they plan to conceive.
Tirzepatide, sold under the brand names Mounjaro and Zepbound, can affect oral contraceptive absorption. Its prescribing information recommends switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting treatment and for four weeks after each dose increase.
Credit: iStock
Parkinson’s disease (PD) symptoms differ between women and men, a new study has found, with potential implications for treatment.
Presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul, the study found that women experienced more severe motor complications and depression. Men, however, had greater cognitive impairment.
“Sex differences in movement disorders remain understudied and undervalued despite having an important impact on clinical outcomes in both real-life and clinical trial settings,” said Dr. Marina Picillo, assistant professor of neurology at AOU San Giovanni di Dio e Ruggi d’Aragona.
Researchers retrospectively analyzed 10 years of clinical data from more than 10,000 Parkinson’s patients examined at a movement disorders clinic in Germany.
The findings showed that women had a greater burden of motor complications and depression. Men were more likely to experience cognitive impairment, REM sleep behavior disorder (RBD) and loss of smell.
“By analyzing data for more than 10,000 PD patients, this study confirmed that depression is more common in women, while RBD, worse cognition, and poorer olfaction are more prevalent in men,” Picillo said. “With good representation of women (40%), it also confirmed a greater female burden of motor complications.”
The findings highlight the need to account for sex differences in Parkinson’s disease management and clinical trial design, particularly given the historical underrepresentation of women in neurological research. However, the factors underlying these differences remain unclear.
Picillo stressed that considering sex differences when tailoring treatment and designing clinical trials could be an important first step toward precision medicine in Parkinson’s disease.
“This would be the very first, basic step for boosting precision medicine in PD,” she said.
Parkinson’s disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing nerve cells in the brain.
Common symptoms include tremors, muscle stiffness, slowed movement and impaired balance. As the disease progresses, patients may have difficulty walking, speaking and performing everyday tasks.
The condition can also cause cognitive impairment, depression, anxiety, sleep disturbances, pain and swallowing difficulties, affecting patients’ independence and quality of life. Although it primarily affects older adults, younger people can also develop Parkinson’s disease.
Parkinson’s disease affected an estimated 11.9 million people worldwide in 2021. The number is projected to reach 25.2 million by 2050, a 112% increase.
There is currently no established way to prevent Parkinson’s disease. However, research suggests that certain lifestyle and environmental factors may influence disease risk.
© $2026 Times Horizon Private Limited